Scott Schoenhaus
Stock Analyst at Keybanc
(3.29)
# 1,034
Out of 4,761 analysts
91
Total ratings
50%
Success rate
2.31%
Average return
Main Sectors:
Stocks Rated by Scott Schoenhaus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SDGR Schrödinger | Maintains: Overweight | $25 → $27 | $22.64 | +19.26% | 4 | Jan 24, 2025 | |
| VEEV Veeva Systems | Maintains: Overweight | $285 → $255 | $225.79 | +12.94% | 15 | Jan 8, 2025 | |
| SLP Simulations Plus | Maintains: Overweight | $40 → $35 | $31.77 | +10.17% | 2 | Jan 8, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Overweight | $12 → $10 | $9.28 | +7.76% | 6 | Jan 8, 2025 | |
| PHR Phreesia | Maintains: Overweight | $28 → $30 | $28.22 | +6.31% | 6 | Jan 8, 2025 | |
| ODD Oddity Tech | Maintains: Overweight | $50 → $52 | $44.00 | +18.18% | 2 | Jan 8, 2025 | |
| LFMD LifeMD | Maintains: Overweight | $10 → $7 | $5.46 | +28.21% | 3 | Jan 8, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $6 | $4.81 | +24.74% | 5 | Jan 8, 2025 | |
| DOCS Doximity | Maintains: Overweight | $70 → $65 | $72.37 | -10.18% | 2 | Jan 8, 2025 | |
| ABSI Absci | Maintains: Overweight | $6 → $5 | $4.96 | +0.81% | 5 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.03 | +32.01% | 4 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 | $5.23 | +72.08% | 5 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $3.01 | +49.75% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $6.82 | +61.29% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $13.17 | +51.86% | 3 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $100 | $108.60 | -7.92% | 3 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $23.20 | - | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $39.72 | - | 8 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Weight | n/a | $11.51 | - | 4 | Sep 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $180 → $250 | $191.04 | +30.86% | 2 | Apr 16, 2021 |
Schrödinger
Jan 24, 2025
Maintains: Overweight
Price Target: $25 → $27
Current: $22.64
Upside: +19.26%
Veeva Systems
Jan 8, 2025
Maintains: Overweight
Price Target: $285 → $255
Current: $225.79
Upside: +12.94%
Simulations Plus
Jan 8, 2025
Maintains: Overweight
Price Target: $40 → $35
Current: $31.77
Upside: +10.17%
Recursion Pharmaceuticals
Jan 8, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $9.28
Upside: +7.76%
Phreesia
Jan 8, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $28.22
Upside: +6.31%
Oddity Tech
Jan 8, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $44.00
Upside: +18.18%
LifeMD
Jan 8, 2025
Maintains: Overweight
Price Target: $10 → $7
Current: $5.46
Upside: +28.21%
GoodRx Holdings
Jan 8, 2025
Maintains: Overweight
Price Target: $7 → $6
Current: $4.81
Upside: +24.74%
Doximity
Jan 8, 2025
Maintains: Overweight
Price Target: $70 → $65
Current: $72.37
Upside: -10.18%
Absci
Jan 8, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $4.96
Upside: +0.81%
Jan 8, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.03
Upside: +32.01%
Jan 8, 2025
Upgrades: Overweight
Price Target: $9
Current: $5.23
Upside: +72.08%
Dec 9, 2024
Initiates: Overweight
Price Target: $4.5
Current: $3.01
Upside: +49.75%
Nov 13, 2024
Maintains: Overweight
Price Target: $10 → $11
Current: $6.82
Upside: +61.29%
Jul 11, 2024
Maintains: Overweight
Price Target: $23 → $20
Current: $13.17
Upside: +51.86%
Jun 5, 2024
Maintains: Overweight
Price Target: $95 → $100
Current: $108.60
Upside: -7.92%
May 10, 2024
Downgrades: Sector Weight
Price Target: n/a
Current: $23.20
Upside: -
Oct 11, 2023
Downgrades: Sector Weight
Price Target: n/a
Current: $39.72
Upside: -
Sep 16, 2022
Initiates: Sector Weight
Price Target: n/a
Current: $11.51
Upside: -
Apr 16, 2021
Upgrades: Overweight
Price Target: $180 → $250
Current: $191.04
Upside: +30.86%